Delix Therapeutics, a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, received regulatory approval and is set to commence recruitment for a Phase 1 clinical trial on its non-hallucinogenic psychoplastogen lead drug candidate, DLX-001.
Psychoplastogens are neuroplasticity-promoting therapeutics and the company’s platform includes several of them. All are based on the work by co-founder and CIO David E. Olson at UC-Davis in the discovery of novel compounds showing significant therapeutic potential without …